Two weeks ago, medtech was on the rise following a rough stretch, but the past week brought the industry slightly back down to earth. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the week (June 4) at 106.96 points, producing a -1.4% dip from the 108.5-point mark […]
Abiomed
Abiomed buys PreCardia and its heart failure treatment system
Abiomed (NASDAQ: ABMD) announced this week that it has acquired PreCardia and its catheter-based system to treat acute decompensated heart failure. The financial terms of the deal were not disclosed in the June 1 announcement. Abiomed officials say the deal complements the company’s product portfolio, expanding options for patients with acute decompensated heart failure. The […]
MedTech 100 roundup: Return to normal following recent spike
After back-to-back all-time best performances, the medtech industry had a slight regression over the course of the last week. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — had been continuously ticking up since the beginning of April, with its mark of 112.25 on April 16 representing an all-time […]
Abiomed stock falls on Q4 results
Abiomed (NSDQ:ABMD) stock is recovering slightly today — a day after its stock fell on fourth-quarter results. ABMD shares were up 0.4% at $324.18 per share in mid-morning trading today, rebounding from a -8% slide to $322.94 per share upon the release of the earnings report yesterday. MassDevice’s MedTech 100 Index — which includes stocks […]
Abbott halts heart pump trial
Abbott (NYSE:ABT) has halted a clinical trial comparing its HeartMate percutaneous heart pump (PHP) ventricular assist device with the Abiomed (NSDQ:ABMD) Impella heart pumps. The Abbott Park, Ill.-based company suspended enrollment in the Shield II investigational device exemption study after a report of decreased impeller speed at the end of a procedure. The HeartMate PHP system […]
MedTech 100 Roundup: Small slide continues
On the back of several weeks of new records and strong performances, the medtech industry has finally hit a snag in its recent ascent. MassDevice‘s MedTech 100 index ended the week (Feb. 26) at 106.65 points, marking a 1.9% dip from the 108.72-point mark set one week before (Feb. 19). This highlights a similar drop from […]
DTW Podcast: Geoff Martha updates Medtronic’s new course; AJAX CEO Duke Rohlen is funding innovation differently
Less than a year into his role as CEO, Geoff Martha and the Medtronic leadership has overseen a significant reorganization of medtech’s largest player. In our closing keynote conversation, Martha says the company is clearing a minor COVID-19 bump and sees open road for the company to continue to grab share from competitors. Martha details […]
Abiomed CEO Michael Minogue appointed as AdvaMed chairperson
Medtech trade group AdvaMed today said it has appointed Abiomed (NSDQ:ABMD) president and CEO Michael Minogue as chairperson of the AdvaMed board of directors, effective immediately. Minogue will serve as chairperson of the trade association’s board of directors for two years. He has been a member of the board since 2007 and a member of the […]
Abiomed touts results of Impella study
Abiomed (NSDQ:ABMD) recently announced positive results from a study of its Impella 5.5 heart pump with SmartAssist. Danvers, Mass.-based Abiomed’s study across 16 U.S. and German locations found a 79% survival rate at explant in 356 patients treated with Impella 5.5 with SmartAssist. A majority of surviving patients recovered native heart function without needing further mechanical […]
MedTech 100 roundup: January ends with a dip
After spending several weeks on the ascent, medtech stocks leveled out a bit to end January, ending a run of several new highs in 2021. MassDevice‘s MedTech 100 index ended the week (Jan. 29) at 104.05 points, marking a -2.2% drop from the 106.4-point mark set at the end of the previous week (Jan. 22). The […]
Jefferies remains optimistic about Abiomed
Analysts are expressing optimism over Abiomed (NSDQ:ABMD) after the company’s third-quarter results saw its stock soar yesterday. Upon releasing the quarterly report, Abiomed’s stock rose 12.4% at $369.45 in the early morning yesterday. The stock price rose as high as $387.23 yesterday but has since dropped to $341.42 at midday today. Jefferies analysts released a report […]
